These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 23460535)

  • 21. TNF/TNFR family members in costimulation of T cell responses.
    Watts TH
    Annu Rev Immunol; 2005; 23():23-68. PubMed ID: 15771565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
    Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
    Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
    [No Abstract]   [Full Text] [Related]  

  • 23. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
    Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
    Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
    Valzasina B; Guiducci C; Dislich H; Killeen N; Weinberg AD; Colombo MP
    Blood; 2005 Apr; 105(7):2845-51. PubMed ID: 15591118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
    Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
    PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
    Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN
    Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
    Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
    J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
    Zapata JM; Perez-Chacon G; Carr-Baena P; Martinez-Forero I; Azpilikueta A; Otano I; Melero I
    Front Immunol; 2018; 9():2618. PubMed ID: 30524423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
    Liu G; Luo P
    Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contextual role of TNFR family members in CD8(+) T-cell control of viral infections.
    Wortzman ME; Clouthier DL; McPherson AJ; Lin GH; Watts TH
    Immunol Rev; 2013 Sep; 255(1):125-48. PubMed ID: 23947352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis.
    Liu B; Li Z; Mahesh SP; Pantanelli S; Hwang FS; Siu WO; Nussenblatt RB
    J Biol Chem; 2008 Mar; 283(13):8202-10. PubMed ID: 18230609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
    Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
    J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OX40/OX40 ligand and its role in precision immune oncology.
    Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
    Cancer Metastasis Rev; 2024 Sep; 43(3):1001-1013. PubMed ID: 38526805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
    Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
    Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.